ESNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ESNT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy, but it is a reasonable hold. The stock is trading near short-term support around 57.25, options sentiment is bearish, insiders have been net sellers, and technicals are mixed with only a mild momentum improvement. While analysts are increasingly constructive on valuation and one major upgrade just hit the name, the broader setup does not yet support an immediate aggressive buy.
Current price is 57.23 after closing down 1.50%, essentially sitting just below the pivot level of 57.252. MACD histogram is positive and expanding, which suggests improving momentum, but RSI_6 at 49.19 is neutral and does not confirm strength. The moving averages remain bearish with SMA_200 above SMA_20 above SMA_5, so the longer trend is still weak. Resistance is nearby at 58.71 and 59.61, while support sits at 55.79 and 54.89. Overall, the chart shows stabilization, not a confirmed uptrend.
["Keefe Bruyette upgraded ESNT to Outperform with a $73 target, citing valuation and cheapness versus tangible book value.", "BofA maintains a Buy rating with a $69 target, showing continued constructive analyst interest.", "MACD is positive and expanding, indicating momentum is improving from a technical standpoint.", "The stock is trading close to book value valuation support, which may attract value buyers."]
["Insiders are selling, and selling activity increased 184.94% over the last month.", "Options positioning is bearish with a 2.72 put-call open interest ratio.", "The stock remains below key resistance and the long-term moving average structure is still bearish.", "Roth Capital cut its target to $65, citing slow growth conditions and maturity in the mortgage insurance business.", "No news catalysts were reported in the last week.", "Hedge funds are neutral with no meaningful accumulation trend."]
No usable latest-quarter financial snapshot was provided, so recent revenue or earnings growth cannot be assessed directly. Based on the analyst commentary, the business appears to be in a mature, slower-growth phase, with affordability constraints limiting new mortgage insurance business. The latest quarter season referenced by analysts is Q1, where delinquencies were modestly higher than expected.
Recent analyst tone is mixed but leaning positive. Keefe Bruyette upgraded the stock to Outperform and set a $73 target, mainly on valuation. BofA remains Buy with a $69 target. Roth Capital kept Buy but lowered its target to $65 due to slow growth and maturity in the business. Barclays is neutral-ish at Equal Weight with targets around $61-$62, and JPMorgan is Neutral at $64. The pros see valuation support and cheapness below book value; the cons are slower growth, macro sensitivity, and a more mature earnings profile.
